0001178913-22-001120.txt : 20220315 0001178913-22-001120.hdr.sgml : 20220315 20220315161010 ACCESSION NUMBER: 0001178913-22-001120 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220314 FILED AS OF DATE: 20220315 DATE AS OF CHANGE: 20220315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pfost Dale R CENTRAL INDEX KEY: 0001394663 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 22741174 MAIL ADDRESS: STREET 1: ACUITY PHARMACEUTICALS INC STREET 2: 3701 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 4 1 zk2227489.xml X0306 4 2022-03-14 0 0001534248 Chemomab Therapeutics Ltd. CMMB 0001394663 Pfost Dale R 1316 JEFFERSON AVE NEW ORLEANS LA 70115 1 1 0 0 Chief Executive Officer American Depositary Shares 2022-03-14 4 P 0 1800 3.98 A 1800 D American Depositary Shares 2022-03-14 4 P 0 700 3.97 A 2500 D Option to Purchase American Depositary Shares 10.05 2021-10-25 4 A 0 459353 0 A 2031-10-25 American Depositary Shares 459353 459353 D Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. The options vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service. /s/ Matthew Rudolph, Attorney-in-Fact for Dale R. Pfost 2022-03-15